Repligen Corporation (RGEN)
NASDAQ: RGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RGEN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $10.47B
- Forward P/E
- 61.77
- EPS (TTM)
- -$0.21
- Dividend yield
- None
- 52-week range
- 100.99 – 198.87
- Day range
- 162.50 – 169.61
- Volume / Avg
- 697.68K / 1.17M
- Beta
- —
- Shares outstanding
- 63.92M
52-week range
RGEN stock today
On Nov 20, RGEN ended the session at $163.81, shedding $6.48 (3.81%), versus the S&P 500's 3.70% decline. At this level, RGEN sits in the middle of its 52-week range of $100.99 to $198.87: 17.6% below the high, set on Sep 28, 2026 and 62.2% above the low. RGEN is down 0.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 0.8%.
Repligen has posted a net loss over the last twelve months (EPS of -$0.21), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Repligen
Company profileRepligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Olivier Loeillot
- Headquarters
- Waltham, MA
- Employees
- 2,000
- IPO year
- 1986
- Website
- repligen.com
Financial highlights
Full financialsIn fiscal 2025, Repligen generated $738.3 million in revenue, up 16.4% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $48.9 million, for a net margin of 6.6% versus a median of 16.4% in the prior 5 years. Gross margin was 52.3% (up from 43.3%) and operating margin 7.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $738.26M | $634.44M | $632.36M | $801.54M | $670.53M |
| Growth | +16.36% | +0.33% | -21.11% | +19.54% | +83.08% |
| Net income | $48.89M | $-25.51M | $35.60M | $185.96M | $128.29M |
| EPS (diluted) | $0.86 | $-0.46 | $0.63 | $3.24 | $2.24 |
Analyst forecast
ForecastConsensus (20 analysts)
buy
Avg. price target
$203.21+24.05%
- Strong buy 3
- Buy 13
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 27, 2026
- EPS actual vs est.
- $0.46 vs $0.46
- Surprise
- 0.00%
RGEN news
All RGEN news- Repligen Corporation (RGEN) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Repligen Corporation (RGEN) Presents at Jefferies Global Healthcare Conference 2026 - SlideshowSeeking Alpha
- Repligen Corporation Issues $1.0 Billion of 0.25% Convertible Senior Notes due 2031NasdaqRGEN, ET
- Repligen: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Repligen Corporation to Present at Jefferies Global Healthcare ConferenceGlobeNewswire
- Repligen announces $1 Billion private convertible senior notes transactionSeeking Alpha
- Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt MaturityNasdaq
- Repligen Announces $1 Billion Private Convertible Senior Notes TransactionGlobeNewswire
Repligen peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HALOHalozyme Therapeutics Inc. | 91.35 | -1.82% | $10.41B | vs RGEN |
| QGENQiagen N.V. | 49.30 | -0.66% | $10.18B | vs RGEN |
| KYMRKymera Therapeutics Inc. | 115.31 | -3.42% | $9.84B | vs RGEN |
| TECHBio-Techne Corp | 72.67 | -0.04% | $11.42B | vs RGEN |
| KRYSKrystal Biotech Inc. | 308.89 | -2.19% | $9.15B | vs RGEN |
| PCVXVaxcyte Inc. | 55.39 | -5.09% | $8.77B | vs RGEN |
| CGONCG Oncology Inc. | 79.47 | -2.97% | $7.10B | vs RGEN |
| TWSTTwist Bioscience Corporation | 103.32 | -7.44% | $7.04B | vs RGEN |
Indexes, lists and sector
Repligen stock FAQ
What is Repligen's stock price today?
RGEN last traded at $163.81 as of Nov 20, 4:00 PM EST, down 3.81% on the day. Prices are delayed at least 15 minutes.
Who is Repligen's CEO?
Mr. Olivier Loeillot is the chief executive officer of Repligen Corporation, which has about 2,000 employees.
What is the RGEN 52-week high?
The 52-week high for RGEN is $198.87 and the 52-week low is $100.99. The stock is currently 17.6% below its high.